Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials.

PubWeight™: 0.80‹?›

🔗 View Article (PMID 26657509)

Published in Oncotarget on March 15, 2016

Authors

Claudia Marchetti1, Francesca De Felice2, Innocenza Palaia1, Angela Musella1, Violante Di Donato1, Maria Luisa Gasparri1, Daniela Musio2, Ludovico Muzii1, Vincenzo Tombolini2, Pierluigi Benedetti Panici1

Author Affiliations

1: Department of Obstetrics-Gynecological Sciences and Urological Sciences, Policlinico Umberto I "Sapienza" University of Rome, Viale del Policlinico, Rome 00161, Italy.
2: Department of Radiotherapy, Policlinico Umberto I "Sapienza" University of Rome, Viale Regina Elena, Rome 00161, Italy.

Associated clinical trials:

Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer (MITO16MANGO2b) | NCT01802749

Evaluation of Optimal Initial Treatment Duration of Bevacizumab in Combination With Standard Chemotherapy in Patients With Ovarian Cancer (BOOST) | NCT01462890